These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 15134820)

  • 21. Cardiovascular effects of aldosterone and post-acute myocardial infarction pathophysiology.
    Cohn JN; Colucci W
    Am J Cardiol; 2006 May; 97(10A):4F-12F. PubMed ID: 16698330
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Regulation of epithelial ion transport by aldosterone through changes in gene expression.
    Bhargava A; Wang J; Pearce D
    Mol Cell Endocrinol; 2004 Mar; 217(1-2):189-96. PubMed ID: 15134817
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Aldosterone synthase inhibitors: pharmacological and clinical aspects.
    Jansen PM; van den Meiracker AH; Jan Danser AH
    Curr Opin Investig Drugs; 2009 Apr; 10(4):319-26. PubMed ID: 19337952
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cardiac S100A1 protein levels determine contractile performance and propensity toward heart failure after myocardial infarction.
    Most P; Seifert H; Gao E; Funakoshi H; Völkers M; Heierhorst J; Remppis A; Pleger ST; DeGeorge BR; Eckhart AD; Feldman AM; Koch WJ
    Circulation; 2006 Sep; 114(12):1258-68. PubMed ID: 16952982
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevention of cardiac remodeling after myocardial infarction in transgenic rats deficient in brain angiotensinogen.
    Lal A; Veinot JP; Ganten D; Leenen FH
    J Mol Cell Cardiol; 2005 Sep; 39(3):521-9. PubMed ID: 15950985
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aldosterone and cardiovascular disease.
    Gaddam KK; Pimenta E; Husain S; Calhoun DA
    Curr Probl Cardiol; 2009 Feb; 34(2):51-84. PubMed ID: 19135616
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Small heat-shock protein Hsp20 attenuates beta-agonist-mediated cardiac remodeling through apoptosis signal-regulating kinase 1.
    Fan GC; Yuan Q; Song G; Wang Y; Chen G; Qian J; Zhou X; Lee YJ; Ashraf M; Kranias EG
    Circ Res; 2006 Nov; 99(11):1233-42. PubMed ID: 17068291
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Aldosterone: from integrative physiology to cellular biology and back.
    Ertl G
    Eur J Clin Invest; 2004 Oct; 34(10):653-5. PubMed ID: 15473889
    [No Abstract]   [Full Text] [Related]  

  • 29. Genomic and nongenomic effects of aldosterone in the rat heart: why is spironolactone cardioprotective?
    Chai W; Garrelds IM; Arulmani U; Schoemaker RG; Lamers JM; Danser AH
    Br J Pharmacol; 2005 Jul; 145(5):664-71. PubMed ID: 15834444
    [TBL] [Abstract][Full Text] [Related]  

  • 30. K(ATP) activation prevents progression of cardiac hypertrophy to failure induced by pressure overload via protecting endothelial function.
    Gao S; Long CL; Wang RH; Wang H
    Cardiovasc Res; 2009 Aug; 83(3):444-56. PubMed ID: 19304734
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Profibrotic effects of aldosterone].
    Van Den Meiracker AH; Huizenga AT; Boomsma F
    Ned Tijdschr Geneeskd; 2004 Jul; 148(31):1532-6. PubMed ID: 15366722
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Blockades of angiotensin and aldosterone reduce osteopontin expression and interstitial fibrosis infiltration in rats with myocardial infarction.
    Zhang YL; Zhou SX; Lei J; Yuan GY; Wang JF
    Chin Med J (Engl); 2008 Nov; 121(21):2192-6. PubMed ID: 19080183
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Celiprolol, a vasodilatory beta-blocker, inhibits pressure overload-induced cardiac hypertrophy and prevents the transition to heart failure via nitric oxide-dependent mechanisms in mice.
    Liao Y; Asakura M; Takashima S; Ogai A; Asano Y; Shintani Y; Minamino T; Asanuma H; Sanada S; Kim J; Kitamura S; Tomoike H; Hori M; Kitakaze M
    Circulation; 2004 Aug; 110(6):692-9. PubMed ID: 15262839
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cardiac aldosterone in subjects with hypertrophic cardiomyopathy.
    Chai W; Hoedemaekers Y; van Schaik RH; van Fessem M; Garrelds IM; Saris JJ; Dooijes D; ten Cate FJ; Kofflard MM; Danser AH
    J Renin Angiotensin Aldosterone Syst; 2006 Dec; 7(4):225-30. PubMed ID: 17318792
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Local myocardial overexpression of growth hormone attenuates postinfarction remodeling and preserves cardiac function.
    Jayasankar V; Bish LT; Pirolli TJ; Berry MF; Burdick J; Woo YJ
    Ann Thorac Surg; 2004 Jun; 77(6):2122-9; discussion 2129. PubMed ID: 15172279
    [TBL] [Abstract][Full Text] [Related]  

  • 36. RALES, EPHESUS and redox.
    Funder JW
    J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):121-5. PubMed ID: 15860254
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cardiac aldosterone overexpression prevents harmful effects of diabetes in the mouse heart by preserving capillary density.
    Messaoudi S; Milliez P; Samuel JL; Delcayre C
    FASEB J; 2009 Jul; 23(7):2176-85. PubMed ID: 19255254
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular mechanisms of myocardial remodeling. The role of aldosterone.
    Delcayre C; Swynghedauw B
    J Mol Cell Cardiol; 2002 Dec; 34(12):1577-84. PubMed ID: 12505056
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Left ventricular remodeling post myocardial infarction].
    Tsutamoto T; Horie M; Hayashi M
    Nihon Rinsho; 2005 Mar; 63 Suppl 3():323-9. PubMed ID: 15813089
    [No Abstract]   [Full Text] [Related]  

  • 40. [The role of the -344C/T polymorphism of the aldosterone synthase gene (CYP11B2) in cardiovascular diseases].
    Boduła A; Dołyk A; Protasiewicz J; Adamiec R
    Postepy Hig Med Dosw (Online); 2007 Dec; 61():838-47. PubMed ID: 18202594
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.